MaxCyte, Inc. Result of AGM (9956D)

TIDMMXCT TIDMTTM

RNS Number : 9956D

MaxCyte, Inc.

02 November 2020

Result of AGM

Gaithersburg, Maryland - 02 November 2020: MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that at its Annual General Meeting held on 30(th) October 2020, all resolutions were duly passed.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

###

Contacts:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer                             +1 301-944-1660 
 Nominated Adviser and Joint Corporate 
  Broker 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                                       +44 (0)20 7886 2500 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                                                      +44 (0)20 7260 1000 
 
   Financial PR Adviser                                                +44 (0)203 709 5700 
   Consilium Strategic Communications                                  maxcyte@consilium-comms.com 
   Mary-Jane Elliott 
   Chris Welsh 
 
   --------------------------------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBUBDBGUGDGGD

(END) Dow Jones Newswires

November 02, 2020 10:52 ET (15:52 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024